Patents Assigned to X4 Pharmaceuticals, Inc.
  • CXCR4 inhibitors and uses thereof
    Patent number: 11780837
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 10, 2023
    Assignee: X4 Pharmaceuticals, Inc.
    Inventors: Elyse Marie Josee Bourque, Renato Skerlj
  • Compositions of CXCR4 inhibitors and methods of preparation and use
    Patent number: 11672793
    Abstract: The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 13, 2023
    Assignee: X4 Pharmaceuticals, Inc.
    Inventor: Karel Marie Joseph Brands
  • Methods for treating cancer
    Patent number: 11357742
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 14, 2022
    Assignees: X4 Pharmaceuticals, Inc., Georgetown University, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Robert D. Arbeit, Paula Marie Ragan, Michael B. Atkins, James W. Mier, David McDermott
  • Methods for treating cancer
    Patent number: 11337969
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as unresectable or metastatic renal cell carcinoma or kidney cancer, in which X4P-001 or a pharmaceutically acceptable salt thereof is administered as monotherapy or in combination with an immune checkpoint inhibitor, such as nivolumab. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: May 24, 2022
    Assignee: X4 Pharmaceuticals, Inc.
    Inventor: Robert D. Arbeit
  • CXCR4 inhibitors and uses thereof
    Patent number: 11332470
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 17, 2022
    Assignee: X4 Pharmaceuticals, Inc.
    Inventors: Elyse Marie Josee Bourque, Renato Skerlj
  • CXCR4 inhibitors and uses thereof
    Patent number: 11306088
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: April 19, 2022
    Assignee: X4 Pharmaceuticals, Inc.
    Inventors: Elyse Marie Josee Bourque, Renato Skerlj
  • Methods for treating immunodeficiency disease
    Patent number: 11219621
    Abstract: The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 11, 2022
    Assignee: X4 Pharmaceuticals, Inc.
    Inventors: Robert D. Arbeit, Paula Marie Ragan
  • Compositions of CXCR4 inhibitors and methods of preparation and use
    Patent number: 11045461
    Abstract: The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 29, 2021
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventor: Karel Marie Joseph Brands
  • CXCR4 inhibitors and uses thereof
    Patent number: 10988465
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 27, 2021
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventors: Elyse Marie Josee Bourque, Renato Skerlj
  • Methods for treating cancer
    Patent number: 10953003
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 23, 2021
    Assignees: X4 PHARMACEUTICALS, INC., GENZYME CORP.
    Inventors: Paula Marie Ragan, Robert D. Arbeit, Kieran James Crowley
  • CXCR4 inhibitors and uses thereof
    Patent number: 10759796
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: September 1, 2020
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventors: Elyse Marie Josee Bourque, Renato Skerlj
  • Methods for treating immunodeficiency disease
    Patent number: 10610527
    Abstract: The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: April 7, 2020
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventors: Robert D. Arbeit, Paula Marie Ragan
  • Compositions of CXCR4 inhibitors and methods of preparation and use
    Patent number: 10548889
    Abstract: The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: February 4, 2020
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventor: Karel Marie Joseph Brands
  • METHODS FOR TREATING CANCER
    Publication number: 20190160051
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as unresectable or metastatic renal cell carcinoma or kidney cancer, in which X4P-001 or a pharmaceutically acceptable salt thereof is administered as monotherapy or in combination with an immune checkpoint inhibitor, such as nivolumab. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.
    Type: Application
    Filed: April 10, 2017
    Publication date: May 30, 2019
    Applicant: X4 Pharmaceuticals, Inc.
    Inventor: Robert D. Arbeit
  • METHODS FOR TREATING CANCER
    Publication number: 20180369229
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 27, 2018
    Applicants: X4 Pharmaceuticals, Inc., Genzyme Corp.
    Inventors: Paula Marie Ragan, Robert D. Arbeit, Kieran James Crowley